NCT06248515 - A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 25, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

December 31, 2026

Conditions

ThymomaThymic Carcinoma

Interventions

DRUG

Sacituzumab govitecan-hziy

10 mg/kg once weekly on Days 1 and 8 of continuous 21-day treatment cycles

Trial Locations (3)

RECRUITING

Lombardi Comprehensive Cancer Center, Georgetown University, Washington D.C.

RECRUITING

Stanford Cancer Institute, Palo Alto

RECRUITING

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack